Transcode Therapeutics (RNAZ) Times Interest Earned (2020 - 2025)
Transcode Therapeutics' (RNAZ) quarterly Times Interest Earned came in at -$413.36 in Q4 2025, down 167.8% YoY from $609.72 in Q4 2024, and down 520.42% on a QoQ basis from -$66.63 in Q3 2025.
Transcode Therapeutics (RNAZ) Times Interest Earned (2020 - 2025) Analysis & Trends
Transcode Therapeutics (RNAZ) has 6 years of Times Interest Earned data on file, last reported at -$413.36 in Q4 2025.
- Quarterly Times Interest Earned fell 167.8% year-over-year to -$413.36 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$159.03 (down 154.68% YoY) and the FY2025 annual result came in at -$1.23, down 26.32% from the prior year.
- Times Interest Earned eased to -$413.36 in Q4 2025, from -$66.63 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $609.72 in Q4 2024 to a low of -$413.36 in Q4 2025.
- A 5-year average of -$64.95 and a median of -$30.59 in 2023 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2021 — Times Interest Earned soared 649.75% — and 2022, when it tumbled 8086.86%.
- Tracing RNAZ's Times Interest Earned over 5 years: stood at $38.68 in 2021, then slumped by 961.44% to -$333.22 in 2022, then climbed by 0.24% to -$332.43 in 2023, then surged by 283.41% to $609.72 in 2024, then sank by 167.8% to -$413.36 in 2025.
- The last three Times Interest Earned figures came in at -$413.36 (Q4 2025), -$66.63 (Q3 2025), and -$360.32 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -413.36 |
| Sep 30, 2025 | -66.63 |
| Jun 30, 2025 | -360.32 |
| Mar 31, 2025 | -55.63 |
| Dec 31, 2024 | 609.72 |
| Sep 30, 2024 | -19.47 |
| Jun 30, 2024 | -132.90 |
| Mar 31, 2024 | -30.04 |
| Dec 31, 2023 | -332.43 |
| Sep 30, 2023 | -31.13 |
| Jun 30, 2023 | -27.12 |
| Mar 31, 2023 | -38.50 |
| Dec 31, 2022 | -333.22 |
| Sep 30, 2022 | -7.07 |
| Jun 30, 2022 | -4.53 |
| Mar 31, 2022 | -86.02 |
| Dec 31, 2021 | 38.68 |
| Sep 30, 2021 | -0.49 |
| Jun 30, 2021 | -0.06 |
| Mar 31, 2021 | -8.52 |